Equity Overview
Price & Market Data
Price: $0.872
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $53,177,336
Volume: 0
Performance Metrics
1 Week: 29.25%
1 Month: 17.85%
3 Months: -5.64%
6 Months: -14.49%
1 Year: 17.47%
YTD: -8.19%
Company Details
Employees: 10
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.